How Health Canada Approves Generic Drugs

The Regulatory Framework

Health Canada regulates all drugs sold in Canada under the Food and Drugs Act and its associated regulations. Generic drugs go through a specific approval pathway called an Abbreviated New Drug Submission (ANDS), which is different from the process for brand-new drugs but equally rigorous in ensuring safety and effectiveness.

The ANDS Process Explained

When a generic manufacturer wants to sell a drug in Canada, they submit an ANDS to Health Canada. This submission must demonstrate that the generic product is pharmaceutically equivalent and bioequivalent to the Canadian reference product (the brand-name drug).

Key Requirements of an ANDS

What Is NOT Required

Generic manufacturers do not need to repeat the full clinical trials conducted for the original brand-name drug. This is because the active ingredient has already been proven safe and effective. The generic only needs to show it delivers that same ingredient to the body in the same way.

This is a key reason why generics are cheaper — they avoid the $1 billion to $2 billion cost of original clinical trials.

The Bioequivalence Study

Bioequivalence testing is the cornerstone of generic drug approval. Here is how it typically works:

Study Design

Healthy volunteers (usually 24 to 36 people) are recruited

Participants take the brand-name drug and the generic drug in separate sessions

Blood samples are taken at regular intervals to measure drug levels

Scientists compare the two drug-level curves

Acceptance Criteria

The generic must fall within 80% to 125% of the brand-name drug on two key measures:

• Cmax: The peak concentration of drug in the blood
• AUC: The total drug exposure over time (area under the curve)

In practice, most approved generics test within 95% to 105% of the brand name. The 80-125% range is a statistical confidence interval, not the actual allowable difference.

Manufacturing Standards

Health Canada inspects generic manufacturing facilities using the same Good Manufacturing Practice (GMP) standards applied to brand-name manufacturers. These inspections cover:

• Facility cleanliness and environmental controls
• Raw material testing and supplier qualification
• Production processes and quality checks
• Batch testing before any product is released
• Record keeping and traceability

Inspections occur both before approval and on an ongoing basis after a drug reaches the market. Facilities that fail inspection face product recalls and market withdrawal.

Post-Market Surveillance

Approval is not the end of Health Canada's involvement. After a generic drug reaches pharmacy shelves, the agency continues monitoring through:

Adverse Reaction Reporting

Health professionals and consumers can report suspected adverse reactions through the Canada Vigilance Program. Health Canada analyzes these reports to detect safety signals.

Periodic Inspections

Manufacturing facilities are re-inspected on a regular cycle. Any quality issues can trigger additional inspections.

Compliance Actions

If problems are identified, Health Canada can:

• Issue public advisories
• Order product recalls
• Suspend or cancel the drug's market authorization

How Canada Compares Internationally

Canada's standards are fully aligned with those of the United States, European Union, and Australia. A generic approved in Canada has met the same scientific bar as one approved by the FDA.

What This Means for You

When you pick up a generic drug at your Canadian pharmacy, you can be confident that:

• It contains the same active ingredient as the brand name
• It has been tested for bioequivalence in human subjects
• It was manufactured in a facility inspected by Health Canada
• It is continuously monitored for safety after reaching the market

Use TransparentMedz to find the lowest prices on Health Canada-approved generics at pharmacies near you. Every generic listed on our platform has gone through this rigorous approval process.